Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 1 | Stem Cell Research & Therapy

Fig. 1

From: Restrained Th17 response and myeloid cell infiltration into the central nervous system by human decidua-derived mesenchymal stem cells during experimental autoimmune encephalomyelitis

Fig. 1

Decidua-derived mesenchymal stem cell (DMSC) treatment delays onset of MOG-experimental autoimmune encephalomyelitis (EAE). Groups of 7–10 C57BL/6 mice were established by MOG35–55 peptide inoculation. a DMSC group animals received 1 × 106 DMSCs at days −1, 3 and 6 post-immunization (p.i.) (arrows). Daily mean clinical scores along EAE course are shown from one representative (n = 10 mice/group) out of five independent experiments. b Statistical significance by unpaired t-test for mean scores at different days after immunization. c Area under the curve (AUC) was calculated from EAE clinical course for each mouse between days 0 and 55 (D0–55) or between days 30 and 55 p.i. (D30–D50), and differences between groups were analyzed using the Mann–Whitney test. Standard error of the means are shown. Data from individual mice included in five independent experiments were used to examine d individual disease onset and e disease incidence at day 20 p.i.; the differences between groups were analyzed by t-test and by Chi-square test, respectively (n for each group is indicated). The bar graphs for representation of the disease incidence contingency table show the numbers of symptomatic and asymptomatic mice at day 20 p.i. for each group. **p < 0.01, ***p < 0.001. ns Not significant

Back to article page